Every 424B that GeoVax Labs, Inc. New (GOVX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow GOVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOVX filings page.
GeoVax Labs, Inc. is registering 402,000 shares of common stock and 30,902 pre-funded warrants, plus 30,902 shares issuable upon their exercise, in a public offering priced at $2.31 per share and $2.30999 per pre-funded warrant. Gross proceeds are expected to be about $1,000,003.31, with estimated net proceeds of approximately $865,000 after placement fees and expenses.
The company will use the funds to advance its vaccine and immunotherapy pipeline, including COVID-19 candidate GEO-CM04S1, oncology therapy Gedeptin and Mpox/smallpox vaccine GEO-MVA, as well as for manufacturing, clinical studies, capital spending and working capital. A concurrent private placement will issue 865,804 unregistered common warrants exercisable at $2.31, which could provide additional cash if exercised.
GeoVax Labs, Inc. files a prospectus supplement that currently permits additional at-the-market sales of its common stock of up to approximately $3,116,227 through A.G.P./Alliance Global Partners under an existing Form S-3 program. This updates an earlier $30,000,000 at-the-market facility under which the company has already sold 4,525,449 shares for $9,269,560.
The supplement reflects limits under General Instruction I.B.6 of Form S-3, tied to GeoVax’s public float. The aggregate market value of common stock held by non-affiliates is stated as $17,804,611, based on 1,728,603 non-affiliate shares at $10.30 per share as of December 8, 2025, and the company notes it has raised $2,818,643 under this instruction in the past twelve months. GeoVax’s stock trades on the Nasdaq Capital Market under the symbol GOVX, with a last reported price of $3.15 on January 23, 2026.
GeoVax Labs, Inc. is supplementing a prospectus covering the resale of up to 1,605,688 shares of common stock by a selling stockholder, incorporating its latest Quarterly Report on Form 10‑Q for the period ended September 30, 2025.
The company reported no revenue in the third quarter from its government contract after BARDA, through the ATI‑RRPV arrangement, terminated that contract for convenience. Third‑quarter 2025 results show a net loss of $6.3 million, bringing the nine‑month net loss to $17.0 million, similar to the prior year despite lower research and development spending.
GeoVax ended the period with $5.0 million in cash and cash equivalents and 29,705,360 shares outstanding, funded largely by multiple equity offerings and warrant exercises that provided about $16.0 million in net financing cash year‑to‑date. Management states that existing cash is expected to fund operations into December 2025 and that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
GeoVax Labs filed a prospectus supplement covering the resale of up to 2,170,000 shares of common stock by a selling stockholder, updating the prospectus with its Form 10‑Q for the quarter ended September 30, 2025.
In the quarter, the company reported a net loss of $6,318,914 and nine‑month net loss of $17,046,348. Revenue was $0 in Q3, reflecting the previously disclosed termination for convenience of a government contract, with $2,489,145 recognized year‑to‑date. Cash and cash equivalents were $5,008,997 and working capital was $4,693,071 as of September 30, 2025. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern, while noting plans to seek additional capital. Financing activities provided $16,041,861 in the nine months ended September 30, 2025. Shares outstanding were 29,705,360 as of November 13, 2025.
GeoVax Labs, Inc. filed a prospectus supplement updating a resale registration covering up to 1,700,000 shares of common stock by a selling stockholder and incorporating the company’s Q3 2025 Form 10‑Q.
For Q3 2025, GeoVax reported a net loss of $6,318,914 and no revenue for the quarter, with nine‑month revenue of $2,489,145 tied to its ATI‑RRPV contract prior to termination for convenience. Cash and cash equivalents were $5,008,997 as of September 30, 2025. The company states that these factors raise substantial doubt about its ability to continue as a going concern.
GeoVax completed several financings in 2025, including offerings closed on March 25, July 2, and September 30, and sales through an ATM program. Shares outstanding were 29,705,360 as of November 13, 2025.
GeoVax Labs filed a prospectus supplement for the resale of up to 975,610 shares of common stock by a selling stockholder, updating the base prospectus with its attached Q3 2025 Form 10-Q.
In the quarter, the company reported a net loss of $6,318,914 and $0 revenue, reflecting the previously disclosed termination-for-convenience of the BARDA-related ATI‑RRPV contract. For the nine months, net loss was $17,046,348. Cash and cash equivalents were $5,008,997, and working capital was $4,693,071. The company raised additional capital in March, July, and September 2025 through stock and warrant offerings and sales under its ATM program.
Management states these factors raise substantial doubt about the company’s ability to continue as a going concern. Shares outstanding were 29,705,360 as of November 13, 2025.
GeoVax Labs, Inc. filed a Rule 424(b)(3) prospectus covering the resale of up to 11,904,768 shares of common stock, issuable upon exercise of September 2025 warrants issued in a September 30, 2025 private placement. The company will not receive proceeds from sales by the selling stockholders; it would receive cash only if holders exercise the warrants. If exercised for cash in full, gross proceeds would be approximately $7.5 million.
The selling stockholders may sell shares from time to time via market or negotiated transactions as detailed under the plan of distribution. GeoVax’s common stock trades on Nasdaq under GOVX; on October 15, 2025, the last reported sale price was $0.5967 per share. Shares outstanding were 29,705,360 as of October 17, 2025. The company notes a Nasdaq bid-price deficiency letter with a compliance date of January 27, 2026.